Your browser is no longer supported. Please, upgrade your browser.
APTX Aptinyx Inc. daily Stock Chart
Aptinyx Inc.
Index- P/E- EPS (ttm)-1.76 Insider Own2.00% Shs Outstand32.96M Perf Week-1.31%
Market Cap124.26M Forward P/E- EPS next Y-2.04 Insider Trans- Shs Float26.92M Perf Month18.93%
Income-58.30M PEG- EPS next Q-0.52 Inst Own69.50% Short Float4.43% Perf Quarter4.43%
Sales5.00M P/S24.85 EPS this Y-62.10% Inst Trans2.00% Short Ratio4.48 Perf Half Y-36.96%
Book/sh4.03 P/B0.94 EPS next Y5.60% ROA-35.90% Target Price13.00 Perf Year-81.55%
Cash/sh4.14 P/C0.91 EPS next 5Y- ROE-37.50% 52W Range2.88 - 32.25 Perf YTD-77.21%
Dividend- P/FCF- EPS past 5Y- ROI-36.80% 52W High-88.31% Beta-
Dividend %- Quick Ratio23.40 Sales past 5Y- Gross Margin- 52W Low30.90% ATR0.26
Employees63 Current Ratio23.40 Sales Q/Q-64.00% Oper. Margin- RSI (14)57.60 Volatility6.06% 7.94%
OptionableNo Debt/Eq0.00 EPS Q/Q-39.50% Profit Margin- Rel Volume0.55 Prev Close3.67
ShortableYes LT Debt/Eq0.00 EarningsAug 13 BMO Payout- Avg Volume265.99K Price3.77
Recom2.00 SMA206.35% SMA509.89% SMA200-66.19% Volume146,352 Change2.72%
Jun-20-19Initiated SVB Leerink Outperform $12
Jan-17-19Downgrade JP Morgan Overweight → Neutral
Nov-15-18Initiated Cantor Fitzgerald Overweight $40
Jul-16-18Initiated Leerink Partners Outperform $35
Jul-16-18Initiated JP Morgan Overweight $30
Jul-16-19 08:54AM  Aptinyx's Shares March Higher, Can It Continue? Zacks
Jul-12-19 08:30AM  Aptinyx Salutes Retiring Chief Scientific Officer and NMDA Receptor Drug Discovery Pioneer, Joseph Moskal GlobeNewswire
Jun-26-19 08:03AM  Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder GlobeNewswire
Jun-18-19 08:27AM  Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference GlobeNewswire +5.67%
Jun-10-19 07:23AM  Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain GlobeNewswire +14.90%
May-28-19 09:33AM  Could The Aptinyx Inc. (NASDAQ:APTX) Ownership Structure Tell Us Something Useful? Simply Wall St. -5.41%
May-14-19 06:27AM  Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-09-19 01:16PM  Were Hedge Funds Right About Dumping Aptinyx Inc. (APTX) ? Insider Monkey
May-07-19 07:23AM  Aptinyx Appoints Henry Gosebruch to Its Board of Directors GlobeNewswire
May-06-19 07:27AM  Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019 GlobeNewswire
May-02-19 06:00AM  Biotech Bets and a Goodbye from a Favorite Expert MoneyShow
Apr-30-19 07:27AM  Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers GlobeNewswire
Apr-18-19 07:27AM  Robust Analgesic Activity of Aptinyxs NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study GlobeNewswire
Apr-04-19 08:00AM  Aptinyx to Present at 18th Annual Needham Healthcare Conference GlobeNewswire
Apr-03-19 07:27AM  Data in Parkinsons Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458 GlobeNewswire +6.83%
Mar-28-19 07:07AM  Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting GlobeNewswire
Mar-27-19 09:00AM  All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy Zacks
Mar-22-19 07:27AM  Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimers & Parkinsons Diseases GlobeNewswire +7.92%
Mar-21-19 07:07AM  Aptinyx Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress GlobeNewswire
Mar-14-19 08:00AM  Aptinyx to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 21, 2019 GlobeNewswire
Mar-06-19 08:00AM  Aptinyx to Present at Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-22-19 08:00AM  Aptinyx to Present at 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire +5.82%
Feb-19-19 07:27AM  Aptinyx Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder GlobeNewswire
Jan-17-19 08:06AM  The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US Benzinga -9.87%
Jan-16-19 04:37PM  Biotech Play Aptinyx Tanks After Drug Trial Fails -66.46%
04:34PM  Why Ford Motor, Snap, and Aptinyx Slumped Today Motley Fool
11:46AM  Here's Why Aptinyx Got Crushed Today Motley Fool
09:19AM  Aptinyx stock falls 67% after phase 2 trial fails to meet primary endpoint MarketWatch
07:27AM  Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy GlobeNewswire
Jan-02-19 08:07AM  Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-20-18 12:50PM  Should You Take Comfort From Insider Transactions At Aptinyx Inc. (NASDAQ:APTX)? Simply Wall St. -18.62%
Dec-11-18 08:27AM  Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacologys Annual Meeting GlobeNewswire
Dec-05-18 08:07AM  Aptinyx to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference GlobeNewswire
Dec-03-18 07:27AM  Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia GlobeNewswire -10.00%
Nov-21-18 07:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Nov-13-18 07:27AM  Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights GlobeNewswire
Nov-12-18 07:07AM  Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans GlobeNewswire
Nov-01-18 07:27AM  Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy GlobeNewswire
Oct-29-18 08:07AM  Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the Society for Neuroscience GlobeNewswire
Sep-25-18 04:01PM  Aptinyx to Present at Cantor Fitzgerald Global Healthcare Conference GlobeNewswire +7.84%
Sep-14-18 08:07AM  Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pains 17th World Congress on Pain GlobeNewswire
Aug-21-18 06:35AM  Aptinyx Presents Preclinical Data from Fast-Track Designated PTSD Program at Military Health System Research Symposium GlobeNewswire
Aug-14-18 06:27AM  Aptinyx Reports Second Quarter 2018 Financial and Business Results GlobeNewswire
Aug-02-18 08:00AM  Aptinyx Initiates Phase 1 Study of NYX-458 GlobeNewswire
Jun-25-18 05:18PM  Aptinyx Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 10:01PM  [$$] Eidos Therapeutics Goes Public, Joining Biotech IPO Flurry The Wall Street Journal
08:41PM  Aptinyx Announces Pricing of Initial Public Offering PR Newswire
Jun-17-18 04:22PM  The IPO Outlook For The Week Of June 18: Pharma, Pharma And More Pharma Benzinga
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.